Candid Therapeutics Teams Up with Ab Studio for Innovative Solutions
Candid Therapeutics, Inc., a dynamic clinical stage biotechnology powerhouse, has announced a groundbreaking partnership with Ab Studio, Inc., a cutting-edge biotech firm focused on antibody discovery. This collaboration aims to explore and develop novel T Cell Engager (TCE) candidates specifically tailored for various autoimmune indications. The collaboration marks a significant advancement in the fight against autoimmune diseases and showcases the commitment of both companies to innovate in the healthcare sector.
Exciting Prospects in T Cell Engagement
Under this new strategic alliance, Candid and Ab Studio plan to leverage their respective expertise to create groundbreaking T Cell Engagers. These innovative therapies aim to enhance the precision of targeting B-cell depletion, a crucial factor in treating autoimmune disorders. Dr. Ken Song, Chairman, President, and CEO of Candid Therapeutics, expressed enthusiasm about the collaboration, emphasizing the potential of their initial program, CND261, which Ab Studio originally designed.
Combining Expertise for Greater Impact
The partnership allows both companies to merge their strengths in biotechnology and antibody engineering. Ab Studio is renowned for its advanced platform in antibody design and engineering, which proposes revolutionary methodologies for developing therapeutic antibodies. Dr. Yue Liu of Ab Studio shared their excitement about collaborating with Candid, highlighting their comprehensive toolkit for antibody discovery.
Details of the Collaboration
As part of the agreement, Candid Therapeutics will retain exclusive rights for the development and commercialization of any programs that arise from this partnership. Though the specific financial terms remain undisclosed, the strategic collaboration signals a promising future for both companies as they aim to accelerate the preclinical efforts in the discovery of innovative therapies.
About Candid Therapeutics, Inc.
Candid Therapeutics is on a mission to lead the market in T-cell engagers, focusing on B-cell depletion therapies to combat autoimmune diseases. Founded in 2024 and based in San Diego, CA, Candid is driven by a team of experienced executives proficient in guiding biopharmaceutical developments. Their focus on emerging therapies is supported by a robust lineup of premier life science investors, pushing boundaries in the biomedical field.
The Vision for Autoimmune Treatment
With two lead B-cell depleting TCE antibody drug candidates already in progress, Candid is keen on exploring TCE's potential across various autoimmune diseases. By targeting different B-cell protein markers and testing diverse depletion strategies, the company is dedicated to advancing treatment options for patients with autoimmune conditions.
About Ab Studio, Inc.
Ab Studio, located in the San Francisco Bay Area, synergizes computational design techniques with conventional antibody discovery methods. This innovative approach aims to produce novel therapeutic antibodies that exhibit superior safety, efficacy, and manufacturing standards, especially for challenging diseases such as cancer and central nervous system disorders. Their various technology platforms include several cutting-edge developments, including Fc-enabled T cell engagers, bispecific antibodies, and catalytic antibodies.
The Drive for Better Antibody Design
Ab Studio’s philosophy revolves around the principle of “quality by design,” where they are committed to developing therapeutic antibodies responding to unmet clinical needs. Their vision aligns with Candid’s goals, promising a fruitful collaboration that may set new standards in the biotechnology industry.
Frequently Asked Questions
What is the focus of the collaboration between Candid Therapeutics and Ab Studio?
The collaboration focuses on discovering and developing novel T Cell Engager candidates to target autoimmune diseases.
Who is the CEO of Candid Therapeutics?
Dr. Ken Song serves as the Chairman, President, and CEO of Candid Therapeutics.
What innovative methods does Ab Studio use?
Ab Studio utilizes computer-aided antibody design combined with traditional techniques to create complex therapeutic antibodies.
What is the goal of Candid Therapeutics?
Candid aims to lead in T-cell engager therapies, particularly for B-cell depletion in autoimmune diseases.
Where is Candid Therapeutics headquartered?
Candid Therapeutics is headquartered in San Diego, California.
